troke is the second leading cause of death worldwide after ischemic heart disease.
Stroke
May 2017 also exist for antihypertensive agents, particularly β-blockers with ADRB1 and thiazide diuretics with NEDD4L. 14 There has been longstanding interest in genetic variants in ADRB1, the gene encoding the β 1 adrenergic receptor (β 1 AR), and their role in cardiovascular disease and treatment response. Several studies have tested these variants with various cardiovascular phenotypes, including blood pressure (BP), 15 heart rate, 16 dilated cardiomyopathy, 17 and composite cardiovascular outcomes. 18 However, less is known about the relation of ADRB1 variants to the pathology and pharmacogenetics of ischemic stroke. The 2 most common and well-studied SNPs in ADRB1 are missense SNPs rs1801252 (A>G; Ser49Gly) and rs1801253 (G>C; Arg389Gly). Pharmacogenetic studies have extensively evaluated these SNPs with different cardiovascular response phenotypes. 14, 19 Among hypertensive individuals, homozygous carriers of the wild-type alleles with serine at codon 49 (Ser49) and arginine at codon 389 (Arg389) may experience greater BP lowering from β-blocker therapy than carriers of the minor allele (Gly49, Gly389), with effect size larger for codon 389 than codon 49. 19 To our knowledge, 1 study has examined the associations of Ser49Gly and Arg389Gly with ischemic stroke, 20 and no study has examined the pharmacogenetic associations of either SNP with ischemic stroke.
The previous literature has identified associations with ischemic stroke for the minor alleles Gly49 and Gly389. 20 In vitro studies indicate Gly49 has greater agonist-induced receptor downregulation, and Gly389 has reduced β 1 AR coupling with Gs-protein. 19 Based on these findings, and the fact that in our study major adverse cardiovascular events (MACE) was primarily composed of recurrent ischemic stroke, we hypothesized that carriers of the minor allele at both loci will have a greater risk of MACE and reduced response to β-blocker therapy as reflected by a higher incidence of MACE among β-blocker-treated carriers compared with noncarriers.
Using data from the SPS3 trial (Secondary Prevention of Small Subcortical Strokes), we investigated associations of Ser49Gly and Arg389Gly with MACE, particularly ischemic stroke, among participants with recent history of small artery ischemic stroke. We also tested pharmacogenetic associations among β-blocker-treated participants. To validate the association with MACE, we tested the association of Ser49Gly with ischemic stroke using consortium data from the SiGN (Stroke Genetics Network).
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Methods
Study Population
The data for this study come from SPS3, an international multicenter randomized controlled clinical trial that evaluated the effect of 2 different antihypertensive and antiplatelet therapy regimens on the rate of recurrent stroke (ClinicalTrials.gov identifier NCT00059306). SPS3 has been described elsewhere. 22 Briefly, 3020 participants ≥30 years old with recent symptomatic small artery ischemic stroke (within 180 days) were recruited and randomized in a 2×2 factorial design to an antiplatelet regimen (aspirin 325 mg daily plus clopidogrel 75 mg daily versus aspirin 325 mg daily plus placebo) and a BP target (lower [also referred to as intensive]: systolic BP (SBP) <130 mm Hg versus higher [also referred to as usual]: SBP 130-149 mm Hg). The primary outcome was recurrent stroke (ischemic or hemorrhagic). Secondary outcomes were rate of cognitive decline and major vascular events, including transient ischemic attack, acute myocardial infarction, noncentral nervous system thromboembolism, and all-cause death. The mean length of follow-up was 3.9±1.9 years (median, 3.8 years). In the SPS3-GENES (SPS3 Genetic Substudy), DNA was collected from saliva samples using OG-500 Oragene DNA self-collection kits (DNA Genotek Inc) on 1139 participants.
The NINDS (National Institute of Neurological Disorders and Stroke) SiGN consortium provided data for the validation, which was a meta-analysis study of the association with presence of ischemic stroke. 21 Data on a total of 41 475 individuals of European and African ancestry in SiGN, excluding SPS3, were analyzed.
Institutional review boards at participating centers for SPS3 and SiGN approved the studies. All participants provided written informed consent.
Genotyping and Imputation
DNA samples collected from SPS3-GENES participants were isolated using the prepIT-L2P kit (PT-LP2-45; DNA Genotek Inc). Genotyping for Ser49Gly (rs1801252) and Arg389Gly (rs1801253) was performed using a TaqMan assay-based QuantStudio polymerase chain reaction system (Life Technologies, Carlsbad, CA). Genotyping call rate was 99% for both Ser49Gly and Arg389Gly. In total, 1126 samples were successfully genotyped. Genotype concordance between genotyped and 1000 Genomes (phase I) imputed data, which became available later, was 99% for Ser49Gly and 96% for Arg389Gly. We tested deviation from Hardy-Weinberg Equilibrium in each ancestry group using the χ 2 test. In SiGN, Ser49Gly and Arg389Gly were imputed from a reference panel that included 1000 Genomes (phase I) and Genome of the Netherlands. Imputation quality for Ser49Gly was 0.984 to 0.998 and for Arg389Gly was 0.982 to 0.993.
Statistical Analysis
Descriptive statistics of baseline and follow-up characteristics on SPS3-GENES participants were compared between participants with and without MACE by the end of the trial. Categorical variables are presented in frequencies, and differences were tested between groups (MACE versus no MACE) using Fisher's exact or χ 2 test, as appropriate. Continuous variables are presented as mean±standard deviation, and differences were tested between groups using Student's t test. Principal components analysis was conducted on high-quality, linkage disequilibrium-pruned genome-wide SNP data using the EIGENSTRAT software. 23 Genome-wide genotyping was performed on the Illumina Omni 5M array. The top 2 principal components separated self-identified Whites, African Americans/Blacks, and Hispanics.
In SPS3-GENES, associations between Ser49Gly and MACE, with and without β-blocker treatment, were tested using Kaplan-Meier survival analysis. MACE comprised stroke (ischemic or hemorrhagic), acute myocardial infarction, and all-cause death. Because 75% of MACE was ischemic stroke, the secondary analysis was of ischemic stroke. Participants were classified as β-blocker-treated if they used a β-blocker at any time during the study. In multivariable Cox proportional hazards regression analyses, covariates included age, sex, ancestry-specific principal components 1 to 2, history of myocardial infarction, history of diabetes mellitus, on-treatment SBP, and β-blocker treatment (except for the model stratified on β-blocker treatment). We selected covariates based on associations with timeto-event in univariate Cox regression analyses with P<0.20; however, age, sex, history of diabetes mellitus, and on-treatment SBP were forced into the model. Because of prior genetic associations of Ser49Gly and Arg389Gly with ischemic stroke, 20 we considered 2-sided P<0.05 as statistically significant for the main effects analyses. Ancestry groups were combined in all analyses given the well-documented functional evidence for these SNPs. Because no prior studies have examined the pharmacogenetic associations of Ser49Gly and Arg389Gly with ischemic stroke, we used a P value threshold of 0.025 (0.05/2 SNPs tested) for the pharmacogenetic analyses. A dominant model of inheritance was assumed, consistent with methodology used in previous studies. 18, 20 We similarly examined ischemic stroke alone. Analyses were performed using SAS 9.4 (Cary, NC) and GraphPad Prism 5.01 (San Diego, CA).
This analysis only included participants with hypertension at baseline, defined as SBP ≥140 mm Hg or diastolic BP ≥90 mm Hg or taking antihypertensive medication(s) at the time of enrollment because we anticipated β-blockers would not be expected to be prescribed in this population in the absence of hypertension. In total, 926 participants were included in the analyses.
Although there was no data set available for validation of MACE because the majority of events were ischemic stroke, and specifically small artery ischemic stroke, we validated our findings using SiGN consortium data. Specifically, meta-analysis of 36 studies in SiGN was conducted for association with presence of ischemic stroke. The SiGN sample (with exclusion of the SPS3 stratum) included 13 449 ischemic stroke cases and 28 026 nonstroke controls. The association was tested under a dominant model by logistic regression, adjusted for sex and ancestry principal components. Stroke subtypes were classified using TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment). 3 We are aware of no stroke data set in which we can validate the pharmacogenetic finding.
Results
Description of Study Participants
Overall, background characteristics of SPS3-GENES participants did not differ significantly by MACE or no MACE status at the time of event or censoring (Table 1 ). There were more men (60.6%), and the average age was 62.2±10.3 years. Treatment with thiazide diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers did not differ by MACE status. However, β-blocker use was significantly higher among those with MACE at follow-up (P=0.002).
The frequency of MACE was 7.2% in the overall sample (67/926). The majority of first events at follow-up was recurrent ischemic stroke (75%), of which 86% was small artery stroke. The remaining events included acute myocardial infarction (n=12), central nervous system hemorrhage (n=4), and death (n=1).
The minor allele frequencies for Ser49Gly were 12%, 26%, and 25% and for Arg389Gly were 29%, 45%, and 15% in whites, African Americans/blacks, and Hispanics, respectively. For both polymorphisms, these are consistent with reference population values in the 1000 Genomes database. Both variants were in Hardy-Weinberg Equilibrium.
SiGN participants have been described elsewhere. 21, 24 Briefly, their mean age was 67 years, half (49%) were women, and White participants comprised 79%. Twenty-five percent of the participants had diabetes mellitus, 68% had hypertension, and 23% had coronary artery disease.
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ADRB1 SNP Associations With MACE
Overall, events were observed in 10.5% of Gly49 allele carriers versus 5.4% of those with the Ser49Ser genotype (P=0.004). Among Gly389 carriers versus noncarriers, event frequencies were 7.5% and 6.9%, respectively (P=0.707). Kaplan-Meier analysis showed that Gly49 allele carriers had a significantly higher incidence of MACE than noncarriers (log-rank P=0.005; Figure 1 ). In additional analyses, Gly49 allele was In the SiGN validation study (n=41 475), multivariable logistic regression analysis showed that Gly49 was significantly associated with presence of small artery ischemic stroke (odds ratio, 1.14; 95% CI, 1.03-1.26; P=0.012), but not other types of ischemic stroke.
Pharmacogenetic Associations
Gly49 allele carriers treated with β-blockers had a significantly higher incidence of MACE when compared with other groups (15.7% versus 5.8%; log-rank P=0.0004; Figure 2 ).
Additionally, Kaplan-Meier analysis showed that among β-blocker-treated individuals, cumulative incidence of MACE was significantly higher among Gly49 allele carriers than among those with Ser49Ser genotype (15.7% versus 7.6%; log-rank P=0.018; Figure III in the online-only Data Supplement). Among individuals with the Ser49Ser genotype, event rates did not differ significantly by β-blocker treatment (log-rank P=0.107).
In stratified multivariable Cox regression analysis, with Ser49Ser and no β-blocker treatment as reference, Gly49 allele carriers treated with β-blockers had significantly increased risk of MACE and ischemic stroke, whereas there were no differences in these outcomes for Ser49Ser treated with β-blockers or Gly49 carriers not treated with β-blockers ( Table 2) . When compared with the 3 other groups, β-blockertreated Gly49 carriers had increased risk of MACE and ischemic stroke (Table 2) . In parallel analyses, we did not find significant pharmacogenetic associations between Arg389Gly and outcomes (Gly389 carrier+β-blocker-treated versus Arg389Arg+β-blocker-treated, P=0.506; and Gly389 carrier+β-blocker-treated versus other groups, P=0.408).
To assess whether achieved BP differed by Ser49Gly genotype and β-blocker use, we compared on-treatment BP, taken at the visit prior to MACE or censoring, between Gly49 allele carriers treated with β-blockers and Gly49 allele Figure 1 . Cumulative incidence of MACE by Ser49Gly genotype among hypertensive participants in SPS3-GENES (SPS3 Genetic Substudy), N=926. MACE indicates major adverse cardiovascular events: stroke, myocardial infarction, all-cause death; 75% of events were ischemic stroke.
Figure 2.
Cumulative incidence of MACE among Gly49 allele carriers treated with β-blockers compared with other groups* in SPS3-GENES (SPS3 Genetic Substudy), N=926. MACE indicates major adverse cardiovascular events: stroke, myocardial infarction, all-cause death; 75% of events were ischemic stroke. βB indicates β-blocker exposed participants. *Other groups included Gly49 allele carriers not treated with β-blockers and noncarriers (Ser49Ser), regardless of β-blocker treatment.
carriers treated with other antihypertensives. β-Blocker-treated Gly49 allele carriers had a higher mean on-treatment SBP, but not diastolic BP, compared with Gly49 carriers treated with other antihypertensives (SBP: 132.4 versus 128.4 mm Hg; P=0.023). Among noncarriers, on-treatment SBP did not differ by β-blocker treatment (P=0.180). Additionally, in spite of higher SBP, β-blocker-treated Gly49 carriers on average took more antihypertensive medications than Gly49 carriers treated with other antihypertensive drugs (4.2 versus 2.5; P<0.001). In parallel analyses, the difference in on-treatment SBP between Gly389 carriers treated with β-blockers and Gly389 carriers treated with other agents was nonsignificant (P=0.641). On average, Gly389 carriers treated with β-blockers were treated with a higher number of antihypertensive medication classes than Gly389 carriers treated with other agents (4.1 versus 2.7; P<0.001).
Discussion
Using data from a randomized controlled trial, we tested the association of β 1 AR polymorphisms with cardiovascular outcomes, composed primarily of ischemic stroke, and evaluated pharmacogenetic associations in β-blocker-treated individuals. Our study population was relatively young (mean age, 62 years), which is comparable to that of similar stroke cohorts. 7 Among participants with a recent history of small artery ischemic stroke, Gly49 allele carriers had an increased risk of recurrent ischemic stroke, particularly small artery stroke, and this finding was corroborated by SiGN consortium metaanalysis that showed Gly49 allele carriers were more likely to have small artery ischemic stroke, but not other types of stroke. These results are consistent with those of a previous small case-control study that reported a higher risk of ischemic stroke among Gly49 allele carriers. 20 Additional analysis suggested that in SPS3-GENES, the association between Gly49 allele and cardiovascular risk may be increased among β-blocker-treated individuals.
The mechanism by which the Gly49 allele may confer risk for ischemic stroke, especially of small arteries, is unclear. It is well-established that β 2 AR is important in mediating peripheral vasodilation; however, recent studies have indicated that this is true only for large conductance vessels, such as the aorta. 25 In smaller arteries, such as small mesenteric resistance arteries [25] [26] [27] and cerebral arteries, 28 vasodilation may primarily depend on β 1 AR stimulation. Another study showed that agonist-induced vasodilation of cerebral arteries is blunted by β 1 AR blockade. 29 If β 1 AR plays a similar role in small subcortical arteries as it does in peripheral resistance arteries and cerebral arteries, it is possible that perturbing the normal functioning of β 1 AR may attenuate its vasodilating effects in small subcortical arteries. The Gly49 variant of β 1 AR might be one such perturbation that may attenuate or even reverse β1AR-induced vasodilation in small subcortical arteries. Evidence from recombinant cell studies have suggested that the Gly49 allele leads to greater agonist-induced β 1 AR downregulation, which means the number of receptors on the cell surface available to bind catecholamines, and, thus, trigger a downstream response, is reduced. 19 In light of β 1 AR's vasodilating effects, the Gly49 variant of β 1 AR may be less responsive to adrenergic stimulation and, consequently, less able to mediate vasodilation in small arteries. Collectively, these studies may in part explain our main effect finding of an association of Gly49 with ischemic stroke of small arteries.
To our knowledge, this is the first study to examine β-blocker pharmacogenetic associations with ischemic stroke, and the data suggest that the main effect finding of risk of MACE and ischemic stroke based on the Gly49 polymorphism may be slightly increased with β-blocker treatment. Specifically, when considering Ser49Ser and no β-blocker treatment as the reference, Gly49 carriers treated with β-blockers had increased risk of adverse outcomes, whereas Ser49Ser participants treated with β-blockers did not. Additionally, Gly49 carriers treated with β-blockers had a 3-fold increased risk, while Gly49 carriers without β-blocker treatment had a 2-fold risk, which suggests that β-blocker treatment may have an amplifying effect on the Gly49 allele. Further, analysis of ontreatment BP and number of antihypertensive drugs suggests that Gly49 participants treated with β-blockers had higher on-treatment BPs, despite being treated with, on average, 1.7 more antihypertensive drugs. In contrast, noncarriers did not have different BPs, based on β-blocker treatment. Collectively, these data suggest Gly49 carriers may be less responsive to the antihypertensive effects of β-blockers, which is consistent with previous studies. 19 A recent Cochrane Review indicated that β-blockers have significantly reduced stroke risk compared with placebo, but have increased stroke risk when compared against other renin-angiotensin system inhibitors and calcium-channel blockers. 30 Our data suggest this increased risk might be particularly important in Gly49 carriers treated Hazard ratio and 95% confidence interval in parentheses; Cox regression models with adjustments for age, sex, principal components 1-2 for ancestry, history of myocardial infarction, history of diabetes mellitus, on-treatment systolic blood pressure. CI indicates confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events (stroke, myocardial infarction, allcause death); and SPS3-GENES, SPS3 Genetic Substudy.
*Other groups included Gly49 allele carriers not treated with β-blockers and noncarriers (Ser49Ser), regardless of β-blocker treatment.
with β-blockers. Further research is needed to provide greater clarity on the role of the Gly49 polymorphism on stroke outcomes in patients treated with β-blockers.
We did not find significant main effects or pharmacogenetic associations for Arg389Gly. While previous studies have found associations of Arg389Gly with cardiovascular and cardiovascular pharmacogenetic phenotypes, 19 Arg389Gly may play a minor role in ischemic stroke pathophysiology and pharmacogenetics when compared with Ser49Gly.
This study has several strengths. In a multiethnic population, Ser49Gly was associated with ischemic stroke in a direction consistent with the previous literature, and we validated this association specifically with small artery ischemic stroke in over 40 000 participants in the SiGN consortium. Furthermore, we may have identified novel pharmacogenetic associations between β-blocker treatment and the ADRB1 Gly49 allele.
This study has limitations that are acknowledged. We were unable to conduct replication analyses of the pharmacogenetic findings because currently, to our knowledge, there are no other replication cohorts of patients with a history of stroke available. Future studies in participants with a previous history of small artery ischemic stroke with medication and genetic information are needed to validate the pharmacogenetic findings. Additionally, we were unable to detect significant associations for some multivariable regression analyses, but the reduced sample sizes and, thus, limited power in these secondary analyses should be considered when interpreting those analyses.
Conclusions
Our study provides evidence that the ADRB1 Gly49 allele may increase cardiovascular risk, particularly for small artery stroke. Additionally, these data suggest that the association between the Gly49 allele and cardiovascular risk may be enhanced by β-blocker treatment. However, because stroke risk was higher in the study population overall, it is difficult to know with certainty if β-blockers in the population are a marker for increased stroke risk, if β-blockers are increasing risk overall and should be avoided, or if, indeed, β-blocker treatment enhances the apparent risk of carrying the ADRB1 Gly49 allele. This highlights the critical importance of future studies to clarify this point because it may have important clinical implications for treatment of patients with small artery stroke.
